Condition

Nausea

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 16 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials16
Recruiting0
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

16 shown
Norepinephrine ED90 Bolus After Spinal Anesthesia in Cesarean SectionNCT06574555 · 2025-04-01
COMPLETED
Acupressure Wristbands for GLP-1RA Related NauseaNCT06939517 · 2024-02-01
ACTIVE_NOT_RECRUITING
Comparison of the Effect of Traditional Method and Eras Protocol in Obesity SurgeryNCT05790317 · 2022-02-14
COMPLETED
The Effects of Inhaled Aromatherapy on Chemotherapy Induced Nausea (CINV) and VomitingNCT04478630 · 2021-08-30
TERMINATED
Effect of Iranian Traditional Medicine Remedy on Chemotherapy Induced Nausea and VomitingNCT02787707 · 2015-10-01
COMPLETED
Auricular Acupressure for Chemotherapy-Induced Nausea and Vomiting in Female Breast Cancer PatientsNCT02403037 · 2015-07-01
COMPLETED
Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based ChemotherapyNCT02407600 · 2015-04-01
UNKNOWN
Evaluation of a Self-Care Toolkit in Surgical Breast Cancer PatientsNCT02387320 · 2014-07-01
UNKNOWN
Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing ChemotherapyNCT01649258 · 2012-09-04
TERMINATED
Daily Tadalafil and Gastric Emptying Time in Diabetic GastroparesisNCT01326117 · 2011-04-01
WITHDRAWN
Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric PatientsNCT00956215 · 2010-05-01
COMPLETED
Medico-economic Evaluation of ENTERRA TherapyNCT00903799 · 2009-06-01
COMPLETED
Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical TrialNCT00475085 · 2006-12-01
COMPLETED
Nexium Study To Suppress Nausea During ChemotherapyNCT00206440 · 2005-08-01
TERMINATED
Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)NCT00092196 · 2002-12-01
COMPLETED
An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)NCT00092183 · 2002-10-10
COMPLETED

Common interventions

AprepitantDRUG2MK0869, aprepitant / Duration of Treatment: 3 daysDRUG2placeboDRUG2Aprepitant placeboDRUG1Comparator: ondansetron / Duration of Treatment: 3 daysDRUG1dexamethasoneDRUG1esomeprazoleDRUG1FOSAPREPITANT (Emend)DRUG1fosaprepitant dimeglumineDRUG1granisetron hydrochlorideDRUG1granisetron transdermal systemDRUG1Implantation of ENTERRA therapyDEVICE1laboratory biomarker analysisOTHER1lactoseDRUG1NorepinephrineDRUG1palonosetron hydrochlorideDRUG1Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla ExtractOTHER1PersumacDRUG1PlaceboOTHER1prochlorperazineDRUG1SeaBandDEVICE1Self-Care ToolkitOTHER1Sham auricular acupressureDEVICE1Standard anti-emetic treatment (5-HT3 receptor antagonists and/or Dexamethasone)DRUG1Surgical Procedure with ERAS ProtocolPROCEDURE1

Trial status mix

COMPLETED9
TERMINATED3
UNKNOWN2
ACTIVE_NOT_RECRUITING1
WITHDRAWN1

Phase mix

NA7
PHASE33
PHASE43
PHASE22
PHASE11
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.